ライフサイエンスコーパス: irritable

1 Irritable/aggressive symptoms were present in 13.9% of t

2 The irritable and headstrong/hurtful dimensions of oppositio

3 rs after ingestion when she became confused, irritable, and agitated.

4 aments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious.

5 a significant risk factor for postinfectious irritable bowel and chronic fatigue syndromes.

6 ructive pathologies of the two main forms of irritable bowel disease (IBD), ulcerative colitis (UC),

7 individuals, and those with colon cancer and irritable bowel disease (IBD), we demonstrated that CD4C

8 rylation was observed in colonic mucosa from irritable bowel disease patients.

9 tive protease pathway in the pathogenesis of irritable bowel disease.

10 centage of individuals with gastrointestinal/irritable bowel disease.

11 d may offer a therapeutic avenue in treating irritable bowel disease.

12 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

13 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

14 valences (per 100 residents) were stable for irritable bowel syndrome (8.3% and 11.4%, respectively)

15 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

16 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

17 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

18 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

19 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

20 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

21 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

22 Irritable bowel syndrome (IBS) affects 7% to 21% of the

23 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

24 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

25 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

26 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

27 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

28 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

29 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

30 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

31 Irritable bowel syndrome (IBS) and inflammatory bowel di

32 Abuse history is common in irritable bowel syndrome (IBS) and is associated with gr

33 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

34 nning to shape a pathophysiological model of irritable bowel syndrome (IBS) and related functional ga

35 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

36 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

37 Approximately 1 in ten patients with irritable bowel syndrome (IBS) believe their IBS began w

38 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

39 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

40 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

41 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

42 unctional gastrointestinal disorders such as irritable bowel syndrome (IBS) has shifted fundamentally

43 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

44 Patients with irritable bowel syndrome (IBS) have increased postprandi

45 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

46 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

47 Irritable bowel syndrome (IBS) is a chronic functional g

48 Irritable Bowel Syndrome (IBS) is a chronic/common condi

49 Irritable Bowel Syndrome (IBS) is a common condition cha

50 Irritable bowel syndrome (IBS) is a common functional ga

51 Irritable bowel syndrome (IBS) is a common gastrointesti

52 Irritable bowel syndrome (IBS) is a common gastrointesti

53 Irritable Bowel Syndrome (IBS) is a functional somatic s

54 Irritable bowel syndrome (IBS) is a gut-brain disorder i

55 Irritable bowel syndrome (IBS) is among the most common

56 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

57 Irritable bowel syndrome (IBS) is characterized by alter

58 Irritable bowel syndrome (IBS) is more common in patient

59 Irritable bowel syndrome (IBS) is one of the most common

60 Irritable bowel syndrome (IBS) is subtyped as IBS with d

61 Patients with irritable bowel syndrome (IBS) often relate symptoms to

62 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

63 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

64 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

65 lay a role in central pain amplification and irritable bowel syndrome (IBS) pathophysiology.

66 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

67 efore aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possib

68 Visceral hypersensitivity in irritable bowel syndrome (IBS) patients has been documen

69 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

70 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

71 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

72 Irritable bowel syndrome (IBS) remains an incompletely u

73 The pathophysiology of irritable bowel syndrome (IBS) remains enigmatic; abnorm

74 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

75 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

76 acy of psychological treatments for reducing irritable bowel syndrome (IBS) symptoms, the mechanisms

77 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

78 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

79 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

80 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

81 st, which has been approved for treatment of irritable bowel syndrome (IBS) with constipation in wome

82 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

83 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

84 showed the benefit of a 5HT(3) antagonist in irritable bowel syndrome (IBS) with diarrhoea (IBS-D) an

85 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

86 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

87 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

88 the most bothersome symptom by patients with irritable bowel syndrome (IBS), and actual distention ma

89 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

90 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

91 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

92 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

93 f these genetic variations with subgroups of irritable bowel syndrome (IBS), functional abdominal pai

94 Irritable bowel syndrome (IBS), functional bloating, fun

95 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

96 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

97 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

98 In patients with irritable bowel syndrome (IBS), pain amplification and h

99 In irritable bowel syndrome (IBS), which is the most common

100 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

101 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

102 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

103 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

104 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

105 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

106 microbiota might also play a similar role in irritable bowel syndrome (IBS).

107 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

108 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

109 important role in the pathophysiology of the irritable bowel syndrome (IBS).

110 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

111 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

112 l nervous system is altered in patients with irritable bowel syndrome (IBS).

113 measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS).

114 he development of drugs for the treatment of irritable bowel syndrome (IBS).

115 the progression and evaluate the severity of irritable bowel syndrome (IBS).

116 nities to develop new therapeutic agents for irritable bowel syndrome (IBS).

117 y be important in the pathophysiology of the irritable bowel syndrome (IBS).

118 n of 5-HT is involved in the pathogenesis of irritable bowel syndrome (IBS).

119 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

120 er-related differences in FGID, particularly irritable bowel syndrome (IBS).

121 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

122 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

123 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

124 sing diet in the management of patients with irritable bowel syndrome (IBS).

125 effective in the treatment of patients with irritable bowel syndrome (IBS).

126 agonists might be involved in development of irritable bowel syndrome (IBS).

127 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

128 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

129 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

130 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

131 red an important pathophysiologic symptom in irritable bowel syndrome (IBS); previous gastrointestina

132 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

133 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

134 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

135 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

136 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

137 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

138 ouse model that reproduces major features of irritable bowel syndrome (long-lasting colon hypersensit

139 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

140 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

141 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

142 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

143 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

144 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

145 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

146 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

147 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

148 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

149 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

150 Clinical studies show that patients with irritable bowel syndrome and colonic diseases frequently

151 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

152 nic gastrointestinal diseases-liver disease, irritable bowel syndrome and dyspepsia, and inflammatory

153 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

154 gastrointestinal tract disorders, including irritable bowel syndrome and gastroesophageal reflux dis

155 with postinfectious complications, including irritable bowel syndrome and Guillain-Barre syndrome.

156 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

157 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

158 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

159 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

160 ensal gut flora in such common conditions as irritable bowel syndrome and inflammatory bowel disease.

161 Both irritable bowel syndrome and inflammatory bowel diseases

162 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

163 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

164 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

165 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

166 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

167 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

168 ely prescribing antibiotics to patients with irritable bowel syndrome can be endorsed.

169 This activation may have relevance to irritable bowel syndrome characterized by lower pain thr

170 in small intestinal bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

171 While interest in bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

172 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

173 The peripheral component is prominent in irritable bowel syndrome developing after infection (pos

174 ease in IBD risk for persons with a previous irritable bowel syndrome diagnosis.

175 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

176 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

177 Traditionally, irritable bowel syndrome has been considered to be a dis

178 Irritable bowel syndrome has been referred to as a funct

179 The study of post-infectious irritable bowel syndrome has revealed the importance of

180 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

181 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

182 ment of the diarrhea-predominant form of the irritable bowel syndrome in women suggests the importanc

183 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

184 It has suggested novel approaches to irritable bowel syndrome including studies of serotonin

185 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

186 Irritable bowel syndrome is characterized by altered sen

187 ecent studies have overthrown the dogma that irritable bowel syndrome is characterized by no abnormal

188 Irritable bowel syndrome is classified as a functional g

189 toms and the strong overlap between GERD and irritable bowel syndrome is due to the influence of NERD

190 noxious stimulation in the context of human irritable bowel syndrome is questionable.

191 interventions are enjoying a renaissance in irritable bowel syndrome management.

192 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

193 orphic nature of some pelvic diseases, e.g., irritable bowel syndrome or cystitis.

194 Irritable bowel syndrome patients form a heterogeneous g

195 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

196 Acupuncture for irritable bowel syndrome provided an additional benefit

197 Irritable bowel syndrome refers to abdominal discomfort

198 Irritable bowel syndrome remains an incompletely underst

199 The role of bacterial overgrowth in irritable bowel syndrome requires further study.

200 Identical irritable bowel syndrome symptoms are probably due to di

201 ortance of low-grade inflammation in causing irritable bowel syndrome symptoms.

202 Noninflammatory irritable bowel syndrome was induced by intracolonic ins

203 233 patients with irritable bowel syndrome were randomly allocated to eith

204 n important clinical feature associated with irritable bowel syndrome which in some patients has been

205 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

206 Irritable bowel syndrome with constipation (IBS-C) affec

207 Patients with irritable bowel syndrome with constipation (IBS-C) and p

208 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

209 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

210 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

211 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

212 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

213 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

214 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

215 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

216 The term "irritable bowel syndrome" was used to search Clinical Ev

217 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

218 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

219 developing after infection (post-infectious irritable bowel syndrome) and this has proved a profitab

220 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

221 e into the development of new approaches for irritable bowel syndrome, a multifactorial disorder for

222 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

223 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

224 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

225 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

226 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

227 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

228 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

229 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

230 EC has been implicated in the development of irritable bowel syndrome, but this remains to be confirm

231 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

232 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

233 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

234 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

235 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

236 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

237 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

238 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

239 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

240 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

241 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

242 ith active UC, inactive UC, Crohn's disease, irritable bowel syndrome, infectious colitis, and micros

243 ute pancreatitis, bacterial gastroenteritis, irritable bowel syndrome, inflammatory bowel disease, he

244 nfection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, po

245 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

246 Irritable bowel syndrome, interstitial cystitis, and oth

247 In women with constipation-predominant irritable bowel syndrome, linaclotide 1000 microg once d

248 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

249 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

250 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

251 ents meeting current diagnostic criteria for irritable bowel syndrome, therapeutic approaches shown t

252 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

253 Irritable bowel syndrome, which affects 5-10% of the pop

254 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat

255 abdominal pain experienced by patients with irritable bowel syndrome, yet the molecules that confer

256 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

257 findings, are nonspecific, and can simulate irritable bowel syndrome.

258 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

259 cupuncture is a cost-effective treatment for irritable bowel syndrome.

260 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

261 be cost-effective for those with more severe irritable bowel syndrome.

262 other involving children suffering from the irritable bowel syndrome.

263 tion between infection with Blastocystis and irritable bowel syndrome.

264 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

265 e clearly established a genetic component in irritable bowel syndrome.

266 abdominal pain and cramping in patients with irritable bowel syndrome.

267 tem, such as chemotherapy-induced emesis and irritable bowel syndrome.

268 ntirely functional, such as in some cases of irritable bowel syndrome.

269 s may have a role in nondiarrhea predominant irritable bowel syndrome.

270 - have developing roles in the treatment of irritable bowel syndrome.

271 overgrowth may be important for treatment of irritable bowel syndrome.

272 in is effective in preventing postinfectious irritable bowel syndrome.

273 ntary and alternative medicine therapies for irritable bowel syndrome.

274 eral hypersensitivity is a characteristic of irritable bowel syndrome.

275 possible therapies for certain patients with irritable bowel syndrome.

276 h mucosa and blood have been demonstrated in irritable bowel syndrome.

277 ses substantial morbidity and postinfectious irritable bowel syndrome.

278 Patients often have a previous diagnosis of irritable bowel syndrome.

279 ultimately provide a cure for patients with irritable bowel syndrome.

280 NR1) have been associated with some forms of irritable bowel syndrome.

281 ergrowth participates in the pathogenesis of irritable bowel syndrome.

282 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

283 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

284 y, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in

285 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

286 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional

287 n who do not fit a specific disorder such as irritable bowel, functional dyspepsia, or abdominal migr

288 mising for helping to differentiate IBD from irritable bowl syndrome and for monitoring disease activ

289 ior, and neural activity between 19 severely irritable children (operationalized using criteria for s

290 suggest that, relative to healthy children, irritable children have deficient reward learning and el

291 ention flexibility, particularly in severely irritable children, which may contribute to emotion regu

292 levels of positive approach-motivation), and irritable (extreme levels of negative emotionality, ange

293 lly and persistently elevated, expansive, or irritable mood and abnormally and persistently increased

294 k the well-demarcated periods of elevated or irritable mood characteristic of bipolar disorder.

295 evels (mean maximum 10,333 IU/liter), and an irritable myopathy on electromyography (88%).

296 eported as useful in differentiating between irritable pouch syndrome and pouchitis.

297 EMA3F), number of children (CADM2 and ESR1), irritable temperament (MSRA) and risk-taking propensity

298 The irritable temperament produced the most significant resu

299 emotion dysregulation when very anxious and irritable youth process threat-related faces.

300 angry expressions) may capture attention in irritable youth.